Under the terms of the agreement, Thermo Fisher will pay up to an additional $100 million in cash upon the completion of certain milestones following the close of the transaction.
As well as coronavirus, Mesa Biotech's point-of-care platform can also detect Influenza A and B, respiratory syncytial virus (RSV) and Strep A. The company is based in San Diego, California and has approximately 500 employees and revenues in 2020 of approximately $45 million.
